• Explore /
  • Videos & Slides
  • / A randomized phase 2 study of combination atezolizumab and varlilumab (CDX-1127) with or without addition of cobimetinib in previously treated unresectable biliary tract cancer.

A randomized phase 2 study of combination atezolizumab and varlilumab (CDX-1127) with or without addition of cobimetinib in previously treated unresectable biliary tract cancer.

Abstract Video & Slides

Presenter

Thatcher Heumann

Thatcher Ross Heumann, MD, MPH

Vanderbilt-Ingram Cancer Center

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Videos & Slides Details

Meeting

2024 ASCO Annual Meeting

Session Type

Rapid Oral Abstract Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Hepatobiliary Cancer - Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT03201458

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr 4017)

DOI

10.1200/JCO.2024.42.16_suppl.4017

Abstract #

4017

Abstract Disclosures

Similar Videos & Slides

Speaker: Anthony B. El-Khoueiry, MD

Speaker: Lorenza Rimassa, MD

Speaker: Yoshiaki Nakamura, MD, PhD

Speaker: Anthony B. El-Khoueiry, MD